HealthDay News — According to a study published in JAMA Oncology, an undated index incorporating gene and molecular alterations can predict survival in non-small cell lung cancer (NSCLC).
Paul Sperduto, MD, from Minneapolis Radiation Oncology, and colleagues updated the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with NSCLC and brain metastases by incorporating recently reported gene and molecular alteration data to develop the Lung-molGPA. Data were analyzed for 2186 patients diagnosed between 2006 and 2014.
The researchers note that the original DS-GPA was based on patient age, Karnofsky Performance Status, extracranial metastases, and number of brain metastases identified in 1833 patients with NSCLC and brain metastases diagnosed between 1985 and 2005.
For the updated Lung-molGPA, significant prognostic factors included the original four factors from the DS-GPA and 2 new factors: EGFR and ALK alterations in patients with adenocarcinoma.
The median survival in the cohort was 12 months and median survival was nearly 4 years for patients with NSCLC-adenocarcinoma and Lung-molGPA scores of 3.5 to 4.0.
“The updated Lung-molGPA incorporating gene alteration data into the DS-GPA is a user-friendly tool that may facilitate clinical decision making and appropriate stratification of future clinical trials,” the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Sperduto PW, Yang TJ, Beal K, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2016. doi:10.1001/jamaoncol.2016.3834. [Epub ahead of print]
Suh JH. Association of Molecular Marker Status With Graded Prognostic Assessment of Lung Cancer With Brain Metastases. JAMA Oncol. 2016. doi:10.1001/jamaoncol.2016.3818. [Epub ahead of print]